Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 12/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14451618 | 0.82 | NPC1 (0.67) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL14451610 | 0.80 | NPC1 (0.57) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL3430125 | 0.78 | NPC1 (1.00) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL29858847 | 0.78 | NPC1 (1.00) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL14451598 | 0.78 | GAA (0.55) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL14451617 | 0.77 | NPC1 (0.68) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL3495450 | 0.75 | AGTR1 (0.58) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL3640134 | 0.74 | LMNA (0.64) | GAANPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL16136343 | 0.74 | TSHR (0.81) | GAANPC1RAB9ATSHR | |
| SCHEMBL855333 | 0.74 | HDAC6 (1.00) | GAANPC1RAB9ASMN1; SMN2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE10A, PDE7A | GAA 107/4885NPC1 1991/4885RAB9A 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.